About this Journal Submit a Manuscript Table of Contents
Depression Research and Treatment
Volume 2013 (2013), Article ID 256841, 8 pages
http://dx.doi.org/10.1155/2013/256841
Review Article

Reduced Treatment-Emergent Sexual Dysfunction as a Potential Target in the Development of New Antidepressants

1Clinical and Experimental Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton SO14 3DT, UK
2Department of Psychiatry, University of Cape Town, Cape Town, South Africa
3Department of Pathophysiology and Transplantation, University of Milan and Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, 20122 Milan, Italy
4First Department of Psychiatry, Eginition Hospital, Athens University Medical School, 11528 Athens, Greece

Received 1 October 2012; Revised 18 December 2012; Accepted 3 January 2013

Academic Editor: Charles B. Nemeroff

Copyright © 2013 David S. Baldwin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. R. DeRogatis and A. L. Burnett, “The epidemiology of sexual dysfunctions,” Journal of Sexual Medicine, vol. 5, no. 2, pp. 289–300, 2008.
  2. R. W. Lewis, K. S. Fugl-Meyer, G. Corona et al., “Definitions/epidemiology/risk factors for sexual dysfunction,” Journal of Sexual Medicine, vol. 7, no. 4, pp. 1598–1607, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Nicolosi, E. O. Laumann, D. B. Glasser, E. D. Moreira, A. Paik, and C. Gingell, “Sexual behavior and sexual dysfunctions after age 40: the global study of sexual attitudes and behaviors,” Urology, vol. 64, no. 5, pp. 991–997, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. R. O. Rosen, W. A. Fisher, I. Eardley, C. Niederberger, A. Nadel, and M. Sand, “The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population,” Current Medical Research and Opinion, vol. 20, no. 5, pp. 607–617, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Dennerstein, P. Koochaki, I. Barton, and A. Graziottin, “Hypoactive sexual desire disorder in menopausal women: a survey of Western European women,” Journal of Sexual Medicine, vol. 3, no. 2, pp. 212–222, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Basson, P. Rees, R. Wang, A. L. Montejo, and L. Incrocci, “Sexual function in chronic illness,” Journal of Sexual Medicine, vol. 7, no. 1, pp. 374–388, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Angst, “Sexual problems in healthy and depressed persons,” International Clinical Psychopharmacology, vol. 13, supplement 6, pp. S1–S3, 1998.
  8. J. M. Cyranowski, J. Bromberger, A. Youk, K. Matthews, H. M. Kravitz, and L. H. Powell, “Lifetime depression history and sexual function in women at midlife,” Archives of Sexual Behavior, vol. 33, no. 6, pp. 539–548, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. J. M. Hegeman, R. M. Kok, R. C. van der Mast, and E. J. Giltay, “Phenomenology of depression in older compared with younger adults: meta-analysis,” British Journal of Psychiatry, vol. 200, pp. 275–281, 2012. View at Publisher · View at Google Scholar
  10. C. F. Lin, Y. Y. Juang, J. K. Wen, C. Y. Liu, and C. I. Hung, “Correlations between sexual dysfunction, depression, anxiety, and somatic symptoms among patients with major depressive disorder,” Chang Gung Medical Journal, vol. 35, no. 4, pp. 323–331, 2012.
  11. S. M. Laurent and A. D. Simons, “Sexual dysfunction in depression and anxiety: conceptualizing sexual dysfunction as part of an internalizing dimension,” Clinical Psychology Review, vol. 29, no. 7, pp. 573–585, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. N. C. C. Vulink, D. Denys, L. Bus, and H. G. M. Westenberg, “Sexual pleasure in women with obsessive-compulsive disorder?” Journal of Affective Disorders, vol. 91, no. 1, pp. 19–25, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Aksaray, B. Yelken, C. Kaptanoǧlu, S. Oflu, and M. Özaltin, “Sexuality in women with obsessive compulsive disorder,” Journal of Sex and Marital Therapy, vol. 27, no. 3, pp. 273–277, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Williams and M. F. Reynolds, “Sexual dysfunction in major depression,” CNS Spectrums, vol. 11, supplement 9, pp. 19–23, 2006. View at Scopus
  15. V. S. L. Williams, D. S. Baldwin, S. L. Hogue, S. E. Fehnel, K. A. Hollis, and H. M. Edin, “Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries: a cross-sectional patient survey,” Journal of Clinical Psychiatry, vol. 67, no. 2, pp. 204–210, 2006. View at Scopus
  16. V. S. L. Williams, H. M. Edin, S. L. Hogue, S. E. Fehnel, and D. S. Baldwin, “Prevalence and impact of antidepressant-associated sexual dysfunction in three European countries: replication in a cross-sectional patient survey,” Journal of Psychopharmacology, vol. 24, no. 4, pp. 489–496, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Serretti and A. Chiesa, “Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis,” Journal of Clinical Psychopharmacology, vol. 29, no. 3, pp. 259–266, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Gartlehner, R. A. Hansen, L. C. Morgan, et al., “Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder. An updated meta-analysis,” Annals of Internal Medicine, vol. 155, no. 11, pp. 772–785, 2011.
  19. K. Demyttenaere and L. Jaspers, “Review: bupropion and SSRI-induced side effects,” Journal of Psychopharmacology, vol. 22, no. 7, pp. 792–804, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. N. Watanabe, I. M. Omori, A. Nakagawa et al., “Mirtazapine versus other anti-depressive agents for depression,” Cochrane Database of Systematic Reviews, vol. 12, no. 2, Article ID CD006528, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Benelli, C. Frigeri, A. Bertolini, and S. Genedani, “Influence of mirtazapine on the sexual behavior of male rats,” Psychopharmacology, vol. 171, no. 3, pp. 250–258, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. A. L. Montejo, N. Prieto, A. Terleira et al., “Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale,” Journal of Psychopharmacology, vol. 24, no. 1, pp. 111–120, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. S. H. Kennedy, S. Rizvi, K. Fulton, and J. Rasmussen, “A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR,” Journal of Clinical Psychopharmacology, vol. 28, no. 3, pp. 329–333, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. I. B. Hickie and N. L. Rogers, “Novel melatonin-based therapies: potential advances in the treatment of major depression,” The Lancet, vol. 378, no. 9791, pp. 621–631, 2011. View at Publisher · View at Google Scholar
  25. A. Zourkova and E. Hadasova, “Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurence of adverse effects,” General Physiology and Biophysics, vol. 22, no. 1, pp. 103–113, 2003. View at Scopus
  26. A. Zourkova, E. Ceskova, E. Hadašová, and B. Ravčuková, “Links among paroxetine-induced sexual dysfunctions, gender, and CYP2D6 activity,” Journal of Sex and Marital Therapy, vol. 33, no. 4, pp. 343–355, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Zourkova, O. Slanar, J. Jarkovsky, I. Palcikova, E. Pindurova, and M. Cvanova, “MDR1 in paroxetine-induced sexual dysfunction,” Journal of Sex & Marital Therapy, vol. 39, no. 1, pp. 71–78, 2013. View at Publisher · View at Google Scholar
  28. I. Nazareth, P. Boynton, and M. King, “Problems with sexual function in people attending London general practitioners: cross sectional study,” British Medical Journal, vol. 327, no. 7412, pp. 423–426, 2003. View at Scopus
  29. S. Read, M. King, and J. Watson, “Sexual dysfunction in primary medical care: prevalence, characteristics and detection by the general practitioner,” Journal of Public Health Medicine, vol. 19, no. 4, pp. 387–391, 1997. View at Scopus
  30. W. Rief, Y. Nestoriuc, A. Von Lilienfeld-Toal et al., “Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis,” Drug Safety, vol. 32, no. 11, pp. 1041–1056, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. E. M. Haberfellner, “A review of the assessment of antidepressant-induced sexual dysfunction used in randomized, controlled clinical trials,” Pharmacopsychiatry, vol. 40, no. 5, pp. 173–182, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. S. J. Rizvi, N. W. Yeung, and S. H. Kennedy, “Instruments to measure sexual dysfunction in community and psychiatric populations,” Journal of Psychosomatic Research, vol. 70, no. 1, pp. 99–109, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. F. Giuliano and W. J. G. Hellstrom, “The pharmacological treatment of premature ejaculation,” BJU International, vol. 102, no. 6, pp. 668–675, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. H. A. Fink, R. MacDonald, I. R. Rutks, and T. J. Wilt, “Trazodone for erectile dysfunction: a systematic review and meta-analysis,” BJU International, vol. 92, no. 4, pp. 441–446, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. D. Baldwin, K. Bridgman, and C. Buis, “Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine,” Journal of Psychopharmacology, vol. 20, no. 1, pp. 91–96, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. D. Baldwin, R. A. Moreno, and M. Briley, “Resolution of sexual dysfunction during acute treatment of major depression with milnacipran,” Human Psychopharmacology, vol. 23, no. 6, pp. 527–532, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. U. Werneke, S. Northey, and D. Bhugra, “Antidepressants and sexual dysfunction,” Acta Psychiatrica Scandinavica, vol. 114, no. 6, pp. 384–397, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. X. H. Hu, S. A. Bull, E. M. Hunkeler et al., “Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate,” Journal of Clinical Psychiatry, vol. 65, no. 7, pp. 959–965, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. H. Dueñas, A. Lee, A. J. M. Brnabic et al., “Frequency of treatment-emergent sexual dysfunction and treatment effectiveness during SSRI or duloxetine therapy: 8-week data from a 6-month observational study,” International Journal of Psychiatry in Clinical Practice, vol. 15, no. 2, pp. 80–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. M. J. Taylor, L. Rudkin, and K. Hawton, “Strategies for managing antidepressant-induced sexual dysfunction: systematic review of randomised controlled trials,” Journal of Affective Disorders, vol. 88, no. 3, pp. 241–254, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. R. Balon and R. T. Segraves, “Survey of treatment practices for sexual dysfunction(s) associated with anti-depressants,” Journal of Sex and Marital Therapy, vol. 34, no. 4, pp. 353–365, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. A. J. Rothschild, “Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday,” American Journal of Psychiatry, vol. 152, no. 10, pp. 1514–1516, 1995. View at Scopus
  43. D. S. Baldwin, “Sexual dysfunction associated with antidepressant drugs,” Expert Opinion on Drug Safety, vol. 3, no. 5, pp. 457–470, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. R. Amiaz, H. G. Pope, T. Mahne et al., “Testosterone gel replacement improves sexual function in depressed men taking serotonergic antidepressants: a randomized, placebo-controlled clinical trial,” Journal of Sex and Marital Therapy, vol. 37, no. 4, pp. 243–254, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. H. G. Nurnberg, P. L. Hensley, A. J. Gelenberg, M. Fava, J. Lauriello, and S. Paine, “Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial,” Journal of the American Medical Association, vol. 289, no. 1, pp. 56–64, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. H. G. Nurnberg, P. L. Hensley, J. R. Heiman, H. A. Croft, C. Debattista, and S. Paine, “Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial,” Journal of the American Medical Association, vol. 300, no. 4, pp. 395–404, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. R. T. Segraves, J. Lee, R. Stevenson, D. J. Walker, W. C. Wang, and R. A. Dickson, “Tadalafil for treatment of erectile dysfunction in men on antidepressants,” Journal of Clinical Psychopharmacology, vol. 27, no. 1, pp. 62–66, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. D. Michelson, K. Kociban, R. Tamura, and M. F. Morrison, “Mirtazapine, yohimbine or olanzapine augmentation therapy for serotonin reuptake-associated female sexual dysfunction: a randomized, placebo controlled trial,” Journal of Psychiatric Research, vol. 36, no. 3, pp. 147–152, 2002. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Fava, C. M. Dording, R. A. Baker et al., “Effects of adjunctive aripiprazole on sexual functioning in patients with major depressive disorder and an inadequate response to standard antidepressant monotherapy: a post hoc analysis of 3 randomized, double-blind, placebo-controlled studies,” Primary Care Companion to the Journal of Clinical Psychiatry, vol. 13, no. 1, pp. e1–e10, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. K.-E. Andersson, “Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction,” Pharmacological Reviews, vol. 63, no. 4, pp. 811–859, 2011. View at Publisher · View at Google Scholar
  51. B. Musicki, T. Liu, G. A. Lagoda, T. J. Bivalacqua, T. D. Strong, and A. L. Burnett, “Endothelial nitric oxide synthase regulation in female genital tract structures,” Journal of Sexual Medicine, vol. 6, supplement 3, pp. 247–253, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. H. G. Nurnberg, S. N. Seidman, A. J. Gelenberg, M. Fava, R. Rosen, and R. Shabsigh, “Depression, antidepressant therapies, and erectile dysfunction: clinical trials of sildenafil citrate (Viagra) in treated and untreated patients with depression,” Urology B, vol. 60, supplement 2, pp. 58–66, 2002. View at Publisher · View at Google Scholar · View at Scopus
  53. R. C. Rosen, S. N. Seidman, M. A. Menza et al., “Quality of life, mood, and sexual function: a path analytic model of treatment effects in men with erectile dysfunction and depressive symptoms,” International Journal of Impotence Research, vol. 16, no. 4, pp. 334–340, 2004. View at Publisher · View at Google Scholar · View at Scopus
  54. G. Wegener, B. H. Harvey, B. Bonefeld et al., “Increased stress-evoked nitric oxide signalling in the Flinders sensitive line (FSL) rat: a genetic animal model of depression,” International Journal of Neuropsychopharmacology, vol. 13, no. 4, pp. 461–473, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. N. Liebenberg, B. H. Harvey, L. Brand, G. Wegener, and C. B. Brink, “Chronic treatment with the phosphodiesterase type 5 inhibitors sildenafil and tadalafil display anxiolytic effects in Flinders Sensitive Line rats,” Metabolic Brain Disease, vol. 27, no. 3, pp. 337–340, 2012. View at Publisher · View at Google Scholar
  56. C. B. Brink, J. D. Clapton, B. E. Eagar, and B. H. Harvey, “Appearance of antidepressant-like effect by sildenafil in rats after central muscarinic receptor blockade: evidence from behavioural and neuro-receptor studies,” Journal of Neural Transmission, vol. 115, no. 1, pp. 117–125, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. S. L. Clark, D. E. Adkins, K. Aberg et al., “Pharmacogenomic study of side-effects for antidepressant treatment options in STARD,” Psychological Medicine, vol. 42, no. 6, pp. 1151–1162, 2012. View at Publisher · View at Google Scholar
  58. K. Kurose, K. Hiratsuka, K. Ishiwata, et al., “Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression,” Psychiatry Research, vol. 198, no. 3, pp. 424–429, 2012. View at Publisher · View at Google Scholar
  59. J. R. Bishop, J. Moline, V. L. Ellingrod, S. K. Schultz, and A. H. Clayton, “Serotonin 2A -1438 G/A and G-protein beta3 subunit C825T polymorphisms in patients with depression and SSRI-associated sexual side-effects,” Neuropsychopharmacology, vol. 31, no. 10, pp. 2281–2288, 2006. View at Publisher · View at Google Scholar · View at Scopus
  60. C. S. Liang, P. S. Ho, and K. T. Chiang, “Su HC. 5-HT(2A) receptor -1438 G/A polymorphism and serotonergic antidepressant-induced sexual dysfunction in male patients with major depressive disorder: a prospective exploratory study,” Journal of Sexual Medicine. In press.
  61. C. M. Dording, D. Mischoulon, I. Shyu, J. E. Alpert, and G. I. Papakostas, “SAMe and sexual functioning,” European Psychiatry, vol. 27l, no. 6, pp. 451–454, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. C. M. Dording, L. Fisher, G. Papakostas et al., “A double-blind, randomized, pilot dose-finding study of maca root (L. Meyenii) for the management of SSRI-induced sexual dysfunction,” CNS Neuroscience and Therapeutics, vol. 14, no. 3, pp. 182–191, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. A. Modabbernia, H. Sohrabi, A. A. Nasehi et al., “Effect of saffron on fluoxetine-induced sexual impairment in men: randomized double-blind placebo-controlled trial,” Psychopharmacology, vol. 223, no. 4, pp. 381–388, 2012. View at Publisher · View at Google Scholar
  64. M. J. Norden, “Buspirone treatment of sexual dysfunction associated with selective serotonin re-uptake inhibitors,” Depression, vol. 2, no. 2, pp. 109–112, 1994. View at Scopus
  65. M. Landen, E. Erikkson, H. Agren, and T. Fahlen, “Effects of buspirone on sexual function in depressed patients treated with selective serotonin reuptake inhibitors,” Journal of Clinical Psychopharmacology, vol. 19, no. 3, pp. 268–271, 1999. View at Publisher · View at Google Scholar
  66. L. F. Fabre, A. H. Clayton, L. C. Smith, I. Goldstein, and L. R. Derogatis, “The effect of gepirone-ER in the treatment of sexual dysfunction in depressed men,” Journal of Sexual Medicine, vol. 9, no. 3, pp. 821–829, 2012. View at Publisher · View at Google Scholar
  67. L. Citrome, “Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant-what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?” International Journal of Clinical Practice, vol. 66, no. 4, pp. 356–368, 2012. View at Publisher · View at Google Scholar
  68. A. H. Clayton, S. H. Kennedy, J. B. Edwards, S. Gallipoli, and C. R. Reed, “The effect of vilazodone on sexual function during the treatment of major depressive disorder,” Journal of Sexual Medicine. In press. View at Publisher · View at Google Scholar
  69. D. S. Baldwin, H. Loft, and M. Dragheim, “A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of LuAA21004 in acute treatment of major depressive disorder (MDD),” European Neuropsychopharmacology, vol. 22, no. 7, pp. 482–491, 2012. View at Publisher · View at Google Scholar
  70. D. Baldwin, J. Hutchison, K. Donaldson, B. Shaw, and A. Smithers, “Selective serotonin re-uptake inhibitor treatment-emergent sexual dysfunction: randomized double-blind placebo-controlled parallel-group fixed-dose study of a potential adjuvant compound, VML-670,” Journal of Psychopharmacology, vol. 22, no. 1, pp. 55–63, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. S. J. Sukoff Rizzo, C. Pulicicchio, J. E. Malberg et al., “5-HT1A receptor antagonism reverses and prevents fluoxetine-induced sexual dysfunction in rats,” International Journal of Neuropsychopharmacology, vol. 12, no. 8, pp. 1045–1053, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. A. Cipriani, T. A. Furukawa, G. Salanti et al., “Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis,” The Lancet, vol. 373, no. 9665, pp. 746–758, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. A. H. Clayton, J. Zajecka, J. M. Ferguson, J. K. Filipiak-Reisner, M. T. Brown, and G. E. Schwartz, “Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder,” International Clinical Psychopharmacology, vol. 18, no. 3, pp. 151–156, 2003. View at Publisher · View at Google Scholar · View at Scopus
  74. S. Langworth, O. Bodlund, and H. Ågren, “Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder,” Journal of Clinical Psychopharmacology, vol. 26, no. 2, pp. 121–127, 2006. View at Publisher · View at Google Scholar · View at Scopus
  75. P. Tran, P. Skolnick, P. Czobor et al., “Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial,” Journal of Psychiatric Research, vol. 46, no. 1, pp. 64–71, 2012. View at Publisher · View at Google Scholar